Steady-state lopinavir levels in third trimester of pregnancy

AIDS

Volumn 21, Issue 8, 2007, Pages 1053-1054

  Lyons, Fiona ^a   Lechelt, Martin ^a   De Ruiter, Annemiek ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; POLYMERASE CHAIN REACTION; PREGNANCY; PRIORITY JOURNAL; STEADY STATE; THIRD TRIMESTER PREGNANCY; VIRUS LOAD;

ADOLESCENT; ADULT; DRUG COMBINATIONS; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTER, THIRD; PYRIMIDINONES; RITONAVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34247633500     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3281053a1e     Document Type: Article

References (5)

1. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, et al., for the PACTG 1026s Study Team. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20:1931-1939.
2. Stek A, Mirochnick M, Capparelli E, Best B, Burchett SK, Hu C, et al., for the Pediatric AIDS Clinical Trials Group (PACTG) 1026 Team. Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG 1026. In: 15th International AIDS Conference. Bangkok, Thailand, 11-16 July 2004 [Abstract LbOrB08].
3. Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, et al., Groupe d'Epidemiologie Clinique du SIDA en Aquitaine. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitorexperienced patients. Antimicrob Agents Chemother 2002; 46:2926-2932.
4. Boffito M, Arnaudo I, Raiteri R, Bonora S, Sinicco A, Di Garbo A, et al. Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS 2002; 16:2081-2083.
5. Kaletra (product labelling). Abbott Laboratories, Abbott Park, Illinois, USA; 2005.